Hepatic Encephalopathy Market is Expected to Showcase a Significant Growth During the Forecast Period (2023-2032), Predicts DelveInsight | Key Companies - Axcella, Umecrine Cognition, Rebiotix, Mallinckrodt, Bausch Health, Patricia Bloom

The Hepatic Encephalopathy Market size in the 7MM was USD 1,563 Million in 2021, which is expected to grow by 2032. Hepatic Encephalopathy Market is expected to grow by 2032 owing to the anticipated approval of emerging therapies and the increasing patient population of Hepatic Encephalopathy in the 7MM.

DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hepatic Encephalopathy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Hepatic Encephalopathy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hepatic Encephalopathy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Hepatic Encephalopathy: An Overview
Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures - for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt - and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production.

HE can occur in individuals with acute or chronic liver (hepatic) disease or individuals whose liver is bypassed by a portosystemic shunt (with no liver disease present). A portosystemic shunt is an abnormal passageway that allows blood from the gastrointestinal tract to bypass the liver. They can be present at birth (congenital) or acquired during life.

Moreover, HE can be associated with more severe symptoms, including reduced alertness, shortened attention span, disruptions in sleep patterns, mild confusion, slowing ability to perform mental tasks, and mood or personality changes. More noticeable changes in memory, concentration, or intellectual function than in minimal hepatic encephalopathy (MHE) may also be observed. HE can also be classified according to whether its presence is overt or covert. When affected individuals have obvious, outward signs and symptoms, the disorder may be referred to as overt hepatic encephalopathy (OHE).

Hepatic Encephalopathy Market Key Facts
• The total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 862,508 cases in 2021. These cases are expected to increase by 2032.
• The diagnosed prevalent cases of Hepatic Encephalopathy in the 7MM are expected to increase at a CAGR of approximately 0.61% for the study period of 2019-2032.
• Among 7MM, the United States has the highest diagnosed prevalent cases of hepatic encephalopathy with 205,664 cases in 2021.
• Hepatic Encephalopathy is divided into two broad categories based on severity, Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). There were a total 123,000+ CHE and 82,000+ OHE cases of Hepatic Encephalopathy in 2021 in the United States.
• In EU-5, the United Kingdom has the highest number of diagnosed prevalent cases of Hepatic Encephalopathy with 28,212 cases in 2021, followed by Germany with 26,672 cases and France with 22,382 cases. While Spain has the least number of cases with 9,326 in 2021.
• In 2021, Japan had 29,464 diagnosed prevalent cases of Hepatic Encephalopathy. These cases are expected to increase by 2032.

Discover How Hepatic Encephalopathy Market will Grow by 2032:
https://www.delveinsight.com/report-store/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hepatic Encephalopathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hepatic Encephalopathy therapies in the market. It also provides a detailed assessment of the Hepatic Encephalopathy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Hepatic Encephalopathy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Hepatic Encephalopathy Epidemiology
The epidemiology section covers detailed insights into the historical, and current Hepatic Encephalopathy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Hepatic Encephalopathy Epidemiology Segmented as
• Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM [2019-2032]
• Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM [2019-2032]
• Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM [2019-2032]
• Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM [2019-2032]

Get Key Insights Into the Evolving Hepatic Encephalopathy Epidemiology Trends:
https://www.delveinsight.com/report-store/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hepatic Encephalopathy Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatic Encephalopathy market or expected to be launched during the study period. The analysis covers the market share by Hepatic Encephalopathy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Hepatic Encephalopathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Leading Companies in the Hepatic Encephalopathy Therapeutics Market Include:
• Salix Pharmaceuticals
• Bausch Health
• Axcella Health, Inc.
• Umecrine Cognition
• Vedanta Biosciences
• Rebiotix
• Mallinckrodt Therapeutics
• Patricia Bloom
And Many Others

Hepatic Encephalopathy Emerging and Marketed Drugs Covered in the Report Include:
• AXA1665: Axcella Health, Inc.
• GR3027 (Golexanolone): Umecrine Cognition
• RBX 2660: Rebiotix
• MNK-6105/MNK-6106: Mallinckrodt Therapeutics
• Xifaxan (Rifaximin/OHE7): Salix Pharmaceuticals/Bausch Health
And Many More

Learn More About the Emerging Therapies & Key Companies in the Hepatic Encephalopathy Therapeutics Market:
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hepatic Encephalopathy Competitive Intelligence Analysis
4. Hepatic Encephalopathy Market Overview at a Glance
5. Hepatic Encephalopathy Background and Overview
6. Hepatic Encephalopathy Patient Journey
7. Hepatic Encephalopathy Epidemiology and Patient Population
8. Hepatic Encephalopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatic Encephalopathy Unmet Needs
10. Key Endpoints of Hepatic Encephalopathy Treatment
11. Hepatic Encephalopathy Marketed Products
12. Hepatic Encephalopathy Emerging Therapies
13. Hepatic Encephalopathy Seven Major Market Analysis
14. Attribute Analysis
15. Hepatic Encephalopathy Market Outlook (7 major markets)
16. Hepatic Encephalopathy Access and Reimbursement Overview
17. KOL Views on the Hepatic Encephalopathy Market.
18. Hepatic Encephalopathy Market Drivers
19. Hepatic Encephalopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Healthcare Reports by DelveIsight
• Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market

• Concussions Market
https://www.delveinsight.com/report-store/concussions-market

• Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market

• Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

• Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

• Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

• Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

• Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

• Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

• Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

• Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

• Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

• Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market

• Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

• Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.